Ludwig's integrated technology development programs, led by Jonathan Skipper, are built to seamlessly move the most promising breakthroughs from the laboratory to clinical testing. We don't wait and hope for others to act on our work, we have dedicated teams to manage every step, from drug discovery to the clinic and beyond. At Ludwig, we test our work against the one measure that matters—human benefit.
Our in-house team has scientific expertise in all aspects of clinical trials management, from study design to managing international networks of sites, from analysis of data and evaluation of results to the design of potential next phases. Our internationally recognized clinical team has wide-ranging partnerships with universities, institutes, not-for-profit research foundations, and pharmaceutical and biotechnology companies.
For more on Ludwig's clinical trials team and their capabilities, click here.
For a complete listing of Ludwig-sponsored clinical trials, click here.
A Phase 1 Study to Evaluate MEDI4736 in Combination With Tremelimumab
Safety and Bio-Imaging Trial of DS-8895a in Patients With Advanced EphA2 Positive Cancers
Phase 2 Study of MEDI4736 in Patients with Glioblastoma
A Phase 1/2 Study of Motolimod (VTX-2337) and MEDI4736 in Subjects with Recurrent, Platinum-Resistant Ovarian Cancer for Whom Pegylated Liposomal Doxorubicin (PLD) is Indicated
A Phase I Study of Intralesional Bacillus Calmette-Guerin (BCG) and Followed by Ipilimumab Therapy in Patients With Advanced Metastatic Melanoma
NY-ESO-1 Vaccine in Combination With Ipilimumab in Patients With Unresectable or Metastatic Melanoma
MAGE-A3 Protein + AS15 as Consolidation for Multiple Myeloma Patients Undergoing Autologous Stem Cell Transplantation
Phase II Study of KW2871 Combined With High Dose Interferon-alpha2b in Patients With Metastatic Melanoma